• Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement for Commercialising Previstage™ GCC Colorectal Cancer Staging Test in China

News & Views

Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement for Commercialising Previstage™ GCC Colorectal Cancer Staging Test in China

Jul 17 2014

Shuwen Biotech Co. Ltd, a diagnostic company focused on licensing, developing and commercialising diagnostic kits and services for unmet clinical needs in China, has announced today that it has formed an alliance with the Canada-based DiagnoCure, Inc to commercialise the Previstage™ GCC colorectal cancer staging test in China. 

Under the exclusive license and collaboration agreement, DiagnoCure has granted Shuwen Biotech an exclusive license to commercialise the Previstage™ GCC colorectal cancer staging test in the Greater China Region (China, Hong Kong, and Taiwan).  Shuwen Biotech will conduct clinical trials in China on an IVD kit format of the Previstage™ test, and obtain a regulatory approval from the Chinese FDA for the kit.  Shuwen Biotech will manufacture the IVD kit in its own manufacturing facilities and market the kit to major Chinese hospitals.  In addition, Shuwen Biotech will also offer the Previstage™ testing service from its own clinical reference lab. 

“Shuwen Biotech is a leading molecular diagnostic company in China led by its Chairman and CEO Jay Z. Zhang, a diagnostic industry veteran, who was formerly a senior vice president at Myriad Genetics.  Collaborating with Jay and his team will undoubtedly create value for both corporations and most importantly help colon cancer patients receive the most appropriate treatment,” commented Dr Yves Fradet, President and Chief Medical Officer of DiagnoCure. 

“The ability to collaborate with DiagnoCure and to market Previstage™ GCC in the Greater China Region provides Shuwen with an exciting opportunity.   We strongly believe in the benefits of Previstage™ GCC to help in staging and better control of colorectal cancer, a condition afflicting unfortunately a growing number of patients in China,” said Mr Jay Z. Zhang.


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

InformEx Zone at CPhl North America

May 07 2024 Pennsylvania, PA, USA

ISHM 2024

May 14 2024 Oklahoma City, OK, USA

ChemUK 2024

May 15 2024 Birmingham, UK

View all events